No products in the cart.
Jardiance Met 12.5mg/1000mg (Empagliflozin/Metformin)
Jardiance Met 12.5mg/1000mg is a high-strength combination tablet of Empagliflozin and Metformin for effective type 2 diabetes management and heart support.
Jardiance Met 12.5mg/1000mg (Empagliflozin/Metformin)
| Active Ingredient | Empagliflozin/Metformin |
|---|---|
| Indication: | Diabetes Type 2 |
| Manufacturer: | Boehringer Ingelheim India Pvt.Ltd |
| Packaging | 10 Tablets in 1 Strip |
| Strength | 12.5mg/1000mg |
Jardiance Met 12.5mg/1000mg combines the power of Empagliflozin and Metformin to offer advanced management of type 2 diabetes. Empagliflozin is a trusted SGLT2 inhibitor that lowers blood sugar by helping the kidneys remove excess glucose through urine. Metformin, on the other hand, reduces glucose production in the liver and improves insulin sensitivity. Together, they provide effective, long-lasting blood sugar control for adults needing intensive therapy.
This higher-strength formulation is suitable for patients who have not responded adequately to lower doses or single medications. In addition to managing blood sugar, Jardiance Met supports weight loss and offers cardiovascular benefits, making it a preferred choice for diabetic individuals with heart-related risks. It is usually taken once or twice daily with food to enhance absorption and minimize side effects like stomach upset. Regular blood tests and medical follow-up are advised while on this medication.
| pack size | 30 Tablets – USD $2.00 Per Tablet, 60 Tablets – USD $1.78 Per Tablet, 90 Tablets – USD $1.66 Per Tablet |
|---|
Be the first to review “Jardiance Met 12.5mg/1000mg (Empagliflozin/Metformin)”
You must be logged in to post a review.
Related Products
Glycomet GP 1 Tablet (Metformin/Glimepiride)
Price range: $7.00 through $42.00
Novonorm 1mg Tablet (Repaglinide)
Price range: $10.00 through $60.00
Glynase Xl 10mg Tablet (Glipizide)
Price range: $3.50 through $21.00
Glizid 40mg Tablet (Gliclazide)
Price range: $5.50 through $33.00
There are no reviews yet.